Previous close | 2.5100 |
Open | 2.5100 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 190.00 |
Expiry date | 2024-07-19 |
Day's range | 2.5100 - 2.5100 |
Contract range | N/A |
Volume | |
Open interest | 115 |
Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable responses, irrespective of whether they had received prior T-cell redirection therapy.1 These data, featured in a poster presentation at the 2024 European
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson (JNJ) closed the most recent trading day at $146.76, moving -0.25% from the previous trading session.